Price Controls and Competition
The Inflation Reduction Act will shift formulary development and contracting dynamics. Time for manufacturers to have a clear, persuasive value story. Learn more from PRECISIONvalue expert Erin Lopata.
The Evolution of Payer Access: Now and Then
Patients already look beyond their prescription benefits for ways to pay. The Inflation Reduction Act is likely to increase demand for new solutions. PRECISIONvalue Chief Medical Officer Dominic Galante explains why.
Download Now: Precision April Events Calendar
The April Events Calendar is here! Stay up to date with all of the upcoming Precision conferences, on-demand events and recent thought leadership!
On Demand: Cell and Gene Therapies – How High Can Prices Go?
Join our experts on April 26, 2023 at 9AM EST as we dive into a powerful 30 minute webinar followed by live Q&A.
This ON24 webinar will discuss how cell and gene therapies can be justifiably priced at different levels. We will explore just how high they can extend and also how we can collectively ensure that patients can access these innovations when they are needed. This discussion will be led by David Carr: Senior Director, Global Pricing and Market Access (PRECISIONadvisors), Richard Macaulay: SVP, Global Pricing and Market Access (PRECISIONadvisors).
Inflation Reduction Act: Squeezing of the Rebate and the Wholesale Acquisition Cost Balloon
When you squeeze a balloon, the air goes somewhere. Same with the cost of drugs. PRECISIONvalue expert Andrew Cournoyer explains the anticipated fallout from the Inflation Reduction Act in this free report.
Part 2: Patient Affordability After the IRA: Potential Impacts
The Inflation Reduction Act (IRA) of 2022 contains a number of health care provisions, including those that will cut Medicare drug spending by an estimated $287 billion over 10 years, according to the congressional budget office. Some of the most widely discussed changes are several near-term changes to the Medicare Part D benefit that are some of the most significant changes in Medicare regulation since the Medicare Modernization Act of 2003. In this free brief (part 2 of 5), PRECISIONvalue expert Ryan Cox outlines how these cuts may impact access and affordability for all.
On-Demand: Cell & Gene Day, 2023
Even as cell and gene therapies inspire hope for patients who previously had none, the path to commercialization is littered with roadblocks. There is a pressing need for increased efficiency, enhanced safety, and innovative approach to pricing and access. How are leading CGTx innovators approaching these challenges? Find out at Cell & Gene Day 2023, a free virtual event, streaming on demand HERE.
Part 1: The Growing Emergence of Biosimilars
Biosimilars are on track to reduce drug costs by $100 billion—but not everyone is on board. The Inflation Reduction Act has provisions that encourage their uptake. Get the details from PRECISIONvalue expert Amy Martin in this free brief (part 1 of 5).
In Healthcare? What you Need to Know about ESG and Proxy Voting
From large institutional investors to smaller quantitative investors, proxy voting guidelines increasingly reference ESG issues such as board diversity and climate change, requiring companies to meet a minimum ESG performance threshold for investors to vote in accord with management.
In this latest edition of Stern IR’s “ESG In Focus” series, we leverage proprietary data on a large number of investors in the healthcare and biotech space to assess their level of engagement around ESG and how ESG factors into their approach to proxy voting.
Article: The Future of Gene Therapies: Three Trends
Since the first gene therapy procedure more than 30 years ago, the field has seen significant advances and development, but also setbacks and issues. What is the future direction for gene therapies? Precision’s Phil Cyr, Richard Macaulay and Andy Kinley identify three future trends and how they might impact safety, manufacturing development, and reimbursement and payment.
